The content on this site is intended for healthcare professionals only
Dr Paul Pharoah discusses research assessing genetic material from several hundred cancer patients across world. This study has identified many new genetic sub-types associated with breast, ovarian and prostate cancer risk and has many potential clinical benefits such as improvements in the effectiveness of breast or prostate cancer screening programmes or the identification of new targets for personalised medicines.
Transforming cancer care in India: The Access Cancer Care Initiative
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies
Best practice in HRRm testing in patients with metastatic prostate cancer
ESMO 2023: Highlights and analysis
Genomic testing: Awareness and effective communication between healthcare professionals and patients
OncoAlert round up July 28th to August 3rd, 2023
Gynaecological cancer: New targets and immunotherapy developments
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
